Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,200
Truist Financial analyst Robyn Karnauskas maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and sets the target price at $1,200.According to TipRanks data, the analyst has a success
Regeneron Stock Slides After Court Rejects Injunction Against Eye Drug Biosimilar, Truist Says
Overweight Quality Stocks With Positive EPS Revision - MS
Express News | Wells Fargo & Co maintains the target price of Regeneron Pharmaceuticals at $1200.00.
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
Wells Fargo Reiterates Overweight on Regeneron Pharmaceuticals, Maintains $1200 Price Target